CANCER

IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy

Next Investors Archived Oct 24, 2019

The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.

City of Hope receives US DoD grant with upside for Imugene

Finfeed Archived Oct 23, 2019

A US Department of Defense Grant has been awarded to renowned City of Hope researchers to fund research into gastric cancer, a disease that disproportionately affects US military service members, veterans, and their beneficiaries.

Ten ‘TechKnows’ to test drive

Finfeed Archived Oct 23, 2019

The TechKnow Invest Roadshow provides retail and institutional investors, as well as brokers, an opportunity to learn more about a range of tech and biotech companies.

Imugene to demonstrate the benefits of combination tumor treatment

Finfeed Archived Oct 21, 2019

Imugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology.

GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer

Next Investors Archived Oct 02, 2019

Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).

Genetic Technologies surges 40% on back of agreement

Finfeed Archived Sep 23, 2019

Provider of world-leading genetic risk assessment test products Genetic Technologies Limited (ASX:GTG), has signed a 3-year Collaboration Agreement with TGen.

Rhythm’s lead biomarker successfully differentiates between cancer and healthy samples

Finfeed Archived Sep 19, 2019

New antibodies for the key lead biomarker used in Rhythm Biosciences' (ASX: RHY) ColoSTAT® test can successfully differentiate between cancer and healthy samples, and the test has now been optimised.

A healthy six pack in a hot sector: Part 2

Finfeed Archived Sep 11, 2019

The S&P/ASX 200 Healthcare Sector blitzed the rest of the market, increasing 12.7% against the ASX 200 which interestingly by the start of September was already back in positive territory, up 4.5%.

A healthy six pack in a hot sector: Part 1

Finfeed Archived Sep 10, 2019

Finfeed has come up with six stocks in the healthcare and bioscience sectors that appear to have plenty going for them in fiscal 2020.